The future of NAMs is not replacement. It is integration.

For decades, preclinical drug development followed a simple logic: 

Test in animals. Then test in humans. 

The FDA's latest guidance on New Approach Methodologies (NAMs) signals a fundamental shift. 

The most important message is not that NAMs are now accepted. 

It's how they are evaluated. 

A NAM does not necessarily need to be fully validated to support regulatory decision-making. 

It needs to be fit-for-purpose. 

That means answering three key questions: 
✅ Does it address a specific regulatory question? 
✅ Does it provide reliable, human-relevant insights? 
✅ Does it strengthen the overall weight of evidence? 

The focus is shifting from tradition to relevance. 

From: 

"Did it work in animals?" 

To: 

"Do we understand how it works in humans?" 

This is a major step forward for drug development. 

But it is equally important to recognize that the future is not about replacing animal models. 

2D cell cultures remain essential for high-throughput screening. 

Animal models continue to provide valuable whole-organism insights. 

Human-relevant NAMs add translational value by helping us better understand human biology, toxicity, and mechanisms of action. 

The real opportunity lies in integrating these approaches through fit-for-purpose study design. 

At abc biopply AG, this philosophy is at the core of our business. 

As Europe's first fully integrated Organoid CRO, we combine: 
🔹 High-throughput 2D screening 
🔹 Validated 3D CoSeedis™ Humanized Multi-Organoid Technology 
🔹 In vivo studies and translational validation 

Our 3D CoSeedis™ platform generates highly standardized micro-tissues composed of hundreds of communicating organoids, combining biological complexity with reproducibility, scalability, and statistical robustness. 

This enables more predictive studies for: 
✅ Drug efficacy 
✅ Safety & toxicity 
✅ Resistance & relapse 
✅ Biomarker discovery 

The FDA's guidance confirms what many of us have long believed: 

The future of NAMs is not replacement. It is integration. 

The winning development strategies will not rely on a single model. They will combine the strengths of 2D systems, humanized organoid technologies, and animal studies to generate the most predictive evidence for patients. 

The future belongs to fit-for-purpose science, where the right model is used at the right stage to answer the right question. 

We are actively seeking collaborations with pharma, biotech, CRO, and academic partners to advance human-relevant, predictive drug development. If you are interested in shaping the future together contact us.